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Abstract
Background. Pediatric spinal ependymomas (SP-EPNs) are rare primary central nervous system tumors with het-
erogeneous clinical course. Considering that ependymomas in children are biologically distinct from their adult 
counterparts, this study aimed to define the molecular landscape of SP-EPNs in children.
Methods. In this retrospective study, we have collected tumor samples from 27 SP-EPN patients younger than 
18 years and carried out the histological review, DNA methylation, and gene expression profiling.
Results. Unsupervised analyses with methylation profiles revealed 2 subgroups where all grade I tumors (n = 11) 
were in Group  1, but the grade II/III tumors split into 2 groups (n  =  7 in Group  1 and n  =  9 in Group  2). The 
Heidelberg classifier assigned Group 1 tumors as spinal myxopapillary ependymomas (SP-MPEs), 5 Group 2 tu-
mors as SP-EPNs, and failed to classify 4 Group 2 tumors. Copy numbers derived from DNA methylation arrays 
revealed subgroup-specific genetic alterations and showed that SP-EPN tumors lack MYCN amplification. Gene 
expression profiling revealed distinct transcriptomic signatures, including overexpression of genes involved in 
oxidative phosphorylation in SP-MPEs that were validated by Western blot analysis. We discovered widespread 
decreases in DNA methylation at enhancer regions that are associated with the expression of oncogenic signaling 
pathways in SP-MPEs. Furthermore, transcription factor motifs for master regulators, including HNF1B, PAX3, and 
ZIC3, were significantly overrepresented in probes specific to distal regulatory regions in SP-MPEs.
Conclusion. Our findings show substantial heterogeneity in pediatric SP-EPN and uncover novel enhancers and 
transcriptional pathways specific to the SP-MPE subgroup, providing a foundation for future therapeutic strategies.
Key Points
• More than half of grade II/III spinal tumors in our cohort are molecularly classified as 
SP-MPEs.
• MYCN amplification is absent in all except one grade II/III spinal tumor.
• A widespread decrease in methylation at enhancer regions distinguishes SP-MPEs from 
SP-EPNs.
Ependymoma is a malignant central nervous system tumor 
that accounts for only 8%–10% of all CNS tumors in children,1,2 
although it is associated with adverse outcomes in younger 
patients compared to adults. Importantly, the molecular basis 
for these differences has remained elusive. Ependymoma oc-
curs throughout the neuraxis—posterior fossa, supratentorial, 
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and spinal cord, presenting in both adults and children. 
The majority of childhood ependymomas (90%) occur in-
tracranially, whereas most tumors in adults arise in the 
spinal cord.3 Spinal ependymoma presents as a centrally 
located mass in the spinal cord that grows slowly and has 
demarcated borders. Pathologically, spinal ependymomas 
are classified by the WHO as grade I, grade II, or grade III. 
Recently, 9 molecular subgroups, with 3 subgroups in each 
of the anatomical regions (posterior fossa, supratentorial, 
spinal), were described using DNA methylation profiling.4 
The 3 subgroups specific to spinal ependymoma included 
subependymoma (SP-SE), myxopapillary ependymoma 
(SP-MPE), and ependymoma (SP-EPN) and showed con-
cordance with the histopathological subtypes. Amplification 
of the oncogene MYCN is observed in small series of 
SP-EPNs in 3 recent studies, 4 grade III tumors,5 3 grade II 
and 10 grade III tumors,6 and 8 grade III tumors,7 and pro-
posed as an additional subgroup of spinal ependymoma 
(SP-EPN-MYCN). Although recurrent oncogenic drivers have 
not been identified, SP-SE harbored 6q deletions, while 
SP-MPE and SP-EPN demonstrated chromosomal instability. 
Moreover, most SP-EPN tumors had a loss of the 22q locus, 
which harbors the tumor-suppressor gene, neurofibromin 
(NF2). Importantly, there is a paucity of studies focused on 
pediatric SP-EPNs since these tumors account for less than 
10% of ependymomas in children.4,8 For example, the DNA-
based classification study with 500 tumor samples had only 
2 SP-EPNs from pediatric patients.4
Given the anatomic location of SP-EPNs in children, ther-
apeutic options are limited and associated with significant 
complications. Most pediatric SP-EPNs, especially grade I, 
occur in the distal regions of the spinal cord, designated 
the filum terminale or conus regions.9 Currently, the only 
effective treatment is maximal safe surgical resection. 
Unfortunately, complete resection can only be achieved in 
patients with focal disease. Radiotherapy is generally re-
commended following incomplete excision, particularly 
for the grade II and III tumors. However, there is a lack 
of evidence regarding the utility of postoperative radio-
therapy, with no consistent improvement in outcomes.10,11 
Moreover, children with SP-EPN are more likely to experi-
ence a more aggressive disease, with higher rates of local 
failure following treatment and more frequent metastasis 
throughout CNS.12
Because these tumors are uncommon, the molecular 
underpinnings of pediatric SP-EPNs remain unknown. We 
hypothesized that molecular heterogeneity exists within 
pediatric SP-EPNs and, further, that understanding the het-
erogeneity will shed light on tumor development, person-
alized therapies, or potential therapeutic targets. To test 
these hypotheses, we performed multi-platform molecular 
profiling of SP-EPNs samples from 27 pediatric patients. 
Our findings reveal 2 distinct groups of pediatric SP-EPNs 
that correspond with recently defined DNA methylation-
based molecular subgroups. We discovered that these 
molecular subgroups show distinct chromosomal copy 
number, transcriptional networks, and epigenetic alter-
ations. Finally, we discovered novel enhancer regions from 
genome-wide methylation alterations in pediatric SP-EPNs.
Materials and Methods
Study Cohort
All tissue samples were radiotherapy and chemotherapy-
naive and prospectively collected either (1) at the local 
tissue bank at Nottingham University Hospital (local ethics 
reference 11/EM/0076) or (2) as part of the Ependymoma 
clinical trials, coordinated by the University of Nottingham, 
United Kingdom (SIOP 1992,13 199914). The histopathology 
of all tumor samples was locally reviewed in each center 
and confirmed by central pathology review in Nottingham. 
Clinical information was obtained via the Children’s Cancer 
and Leukaemia Group, United Kingdom. The study was 
conducted following the Declaration of Helsinki. Tissue 
samples were obtained during the surgical resection of 
the tumor. All frozen samples were snap-frozen and stored 
at −80°C. Formalin-fixed paraffin-embedded (FFPE) tissue 
was collected as scrolls or unstained slides. A total of 27 
patients with SP-EPN were included in the study.
RNA and DNA Extraction
For frozen tissue tumor samples, RNA was extracted 
using miRNeasy Micro Kit (QIAGEN) and DNA was ex-
tracted using QIAamp DNA Mini Kit (QIAGEN), according 
Importance of the Study
Our study, for the first time, describes the mo-
lecular characterization of rare spinal tumors 
in children. The DNA methylation array anal-
ysis segregates 27 pediatric SP-EPNs into 2 ro-
bust primary molecular subgroups. All grade 
I, myxopapillary tumors are grouped whereas 
grade II/III spinal tumors are distributed into 
2 molecular subgroups. The Heidelberg meth-
ylation classifier assigns tumors to previously 
defined subgroups: SP-MPEs, SP-EPNs, and 
fails to classify 4 tumors as spinal ependymal 
tumors. None of the classified tumors has 
MYCN amplification in our cohort. Tumor sam-
ples in the SP-MPE subgroup show high ex-
pression of genes associated with oxidative 
phosphorylation and a widespread decrease 
in DNA methylation at enhancer regions com-
pared to the SP-EPN subgroup. These findings 
enhance our understanding of the molecular 
landscape of the pediatric SP-EPN and point to 
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to manufacturer’s guidelines. For FFPE tumor samples, 
RNA and DNA were extracted simultaneously using 
AllPrep DNA/RNA Mini Kit (QIAGEN) according to the 
manufacturer’s guidelines. Following RNA extraction, 
DNase I  digestion step was carried out to remove DNA 
fragments. RNA quality control check was performed be-
fore microarray profiling. Similarly, DNA extraction was 
followed by bisulfite treatment before DNA methyla-
tion (DNA methylation: Zymo, product code D5001; DNA 
cleanup & concentrator-5: Zymo, D4013).
Genome-Wide DNA Methylation Profiling
Samples were analyzed on the human Infinium 
MethylationEPIC BeadChips or the Illumina Infinium 
HumanMethylation450K at the UCL Genomics according 
to the manufacturer’s instructions. All analyses were 
performed in the R Statistical Environment (v3.6.0). 
Raw genome-wide methylation data (IDAT files) gener-
ated from both frozen and FFPE derived tissue were pre-
processed using the minfi Bioconductor package version 
1.30.0.15 Illumina 450K and EPIC BeadChip arrays were 
combined by selecting common probes that are present 
on both arrays. The Illumina preprocessing method that 
includes background subtraction and control normaliza-
tion was selected to generate methylated values. To ac-
count for possible batch effects due to divergent protocols 
for fresh frozen and FFPE material, and type of array (450K 
or EPIC), a batch adjustment was performed using a linear 
model.16 The residuals from the linear model were back-
transformed to the intensity scale, and methylation beta 
values were calculated as described in Illumina’s proto-
cols. Subsequently, probes were removed according to 
the following filtering criteria: (1) mapping to the X and 
Y chromosomes, (2) containing a single-nucleotide pol-
ymorphism (dbSNP137 Common) at the targeted CpG 
site or the single-base extension site, (3) nonspecific 
probes, and (4) not unique to the human reference ge-
nome (hg19) allowing for one mismatch. In total, 401 
060 probes were retained for downstream analysis. The 
SP-EPN molecular subgroup status was determined by the 
Heidelberg brain tumor classifier version 2.0 (https://www.
molecularneuropathology.org/mnp).
Gene Expression Profiling
RNA was hybridized to Human Affymetrix Clariom 
TM D arrays according to the manufacturer’s instruc-
tions. These arrays have more than 6.5 million probes 
interrogating both protein-coding and long noncoding 
genes. Array data were preprocessed with the Robust 
Multi-array Average method using the Affymetrix Power 
Tool (APT v2.10.2.2) and annotated with NetAffx annota-
tion Release 36.17 The log2 transformed expression values 
for protein-coding genes were used for the subsequent 
analyses. Expression values were mapped from probe set 
to a unique gene and the probe set with the highest vari-
ance in expression was selected when multiple probe sets 
were mapped to the same gene. The final filtering step left 
a total of 25 272 genes.
DNA Methylation-Based Clustering and Copy 
Number Alteration Analyses
Consensus clustering was performed to detect ro-
bust sample groups using the R Bioconductor package, 
ConsensusClusterPlus. The top 5000 CpG probes exhib-
iting the greatest median absolute deviation were used for 
the consensus clustering analysis. Specifically, 80% of the 
original 27 samples were randomly subsampled without 
replacement and partitioned into 2–10 major clusters 
using the hierarchical clustering (HCL) algorithm, which 
was repeated 1000 times. The number of clustering was 
determined by 3 factors: the average pairwise consensus 
matrix within consensus clusters, the delta plot of the rel-
ative change in the area under the cumulative distribution 
function curve, and the average silhouette distance for 
consensus clusters. Silhouette analysis was used to eval-
uate sample membership following consensus HCL, and 
SigClust was used to determine the statistical significance 
of subgroups. Also, a non-negative matrix factorization 
(NMF) clustering algorithm was used for the unsuper-
vised subgroup discovery using the 5000 most variable 
CpG probes. NMF (R package: NMF version 0.21) was per-
formed for 1000 resampling iterations using the default 
parameters. A comparison was made between consensus 
HCL and NMF using a Rand Index and assessed statisti-
cally by permutation of sample labels and repetition of the 
Rand Index calculation to generate a null distribution.
Copy number segmentation was performed from 450K 
and EPIC genome-wide methylation arrays using the 
conumee package version 1.17.0. Segment files were gen-
erated for each subgroup.
Gene Set Enrichment Analysis of Gene 
Expression Data
Gene set enrichment analysis (GSEA) was performed using 
the javaGSEA application version 4.0.2. The gene list output 
from the differential expression analysis with an eBayes ad-
justed moderated t-statistic linear regression model was 
ranked by calculating a rank score of each gene as −log10 
(P value) × sign (FC), in which FC is the fold change (ex-
pressed as log2 [expression in MPE/expression in SP]) and 
the sign depends on whether the gene is upregulated or 
downregulated.16 A  pre-ranked GSEA analysis was per-
formed using 1000 permutations. The gene sets from MSigDB 
collections, particularly C2: BioCarta and Kyoto Encyclopedia 
of Genes and Genomes pathway databases, and C5: Gene 
Ontology database were used for the GSEA analysis.
Integrative DNA Methylation and Gene 
Expression Analysis
We used profiles from 27 pediatric SP-EPN tumor samples 
with both methylation and expression data sets. Using the 
Enhancer linking by methylation/expression relationships 
(ELMER) R package (version 2.6.1) in supervised mode, the 
methylation and expression data were integrated to inves-
tigate gene regulatory networks and identify related master 
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the processed methylation data β values, as described above, 
were used, combined with processed microarray expression 
data. Only distal probes were selected, defined as probes 
at least ±2  kb away from a transcription start site (TSS). 
The moderated t-statistic based on the empirical Bayesian 
method (R package: Limma) was used to determine differ-
entially methylated distal probes between 2 molecular sub-
groups.16 For these altered probes, the 20 closest genes (10 
upstream and 10 downstream) were then identified and the 
association between probe methylation and gene expres-
sion was tested with a non-parametric Mann–Whitney U 
test, using the false discovery rate (FDR) for multiple testing 
correction. Significant probe–gene pairs were defined as 
pairs with an FDR less than 0.05. Next, a transcription factor 
binding motif enrichment analysis was performed on the 
regions (±250  bp) around the probes of significant hyper- 
and hypomethylated probe–gene pairs using Fisher’s exact 
test. A motif was considered enriched if the odds ratio was 
more than 1.1, it occurred more than 10 times in the probe 
set regions, and the FDR was less than 0.05. Finally, poten-
tial upstream master regulator transcription factors were 
determined by comparing the average methylation value 
of all probes associated with a motif with the expression 
values of genes annotated as a transcription factor with a 
Mann–Whitney U test. For this test, we assumed that lower 
transcription factor expression corresponds to increased 
methylation levels. After ranking by P value, the top 5% of 
transcription factors were considered master regulators.
Western Blots
Normal human fetal spine protein lysate was purchased 
from the GeneTex International Corporation (product 
code GTX24529). Total protein was extracted from using 
the Qproteome FFPE Tissue Kit (QIAGEN) following the 
manufacturer’s guidelines. Extracted proteins were quan-
tified using Bradford’s assay. For Western blot analysis, the 
total protein (30 µg) was loaded into 12% SDS-PAGE gels. 
Proteins were then transferred into polyvinylidene fluoride 
(PVDF) membranes using a wet transfer tool (Bio-Rad). 
Membranes were first blocked with 5% milk before probing 
with Total OXPHOS human WB antibody cocktail (Abcam, 
ab110411) at 4°C overnight. The next day, the membranes 
were washed with tris-buffered saline and Tween 20 (TBST) 
before probing with the secondary antibody (anti-mouse 
or anti-rabbit). Proteins were visualized via chemilumi-
nescence (Signal Fire Elite ECL reagent, product number 
12757P). Housekeeping protein GAPDH was used as an in-
ternal loading control (Cell Signalling, product code 97166). 
The Images were scanned using (FujiFilm 3000) and the re-
sulting data were analyzed (Image J software).
Results
Our SP-EPN cohort included 27 patients, all of whom were 
children younger than 18  years (median age 12.3  years; 
range 4.3–16.8 years). Of these, 17 were males and 10 were 
females. Histologic subtypes included tumors classified 
as WHO grade I (n = 11), WHO grade II (n = 14), and WHO 
grade III (n = 2; Table 1).
DNA Methylation Profiling Reveals 2 Molecular 
Subgroups of Pediatric S-EPN
To identify and validate molecular subgroups in our 27 pe-
diatric S-EPNs, we analyzed DNA methylation array data 
from 27 S-EPN tumor samples by using 2 distinct unsuper-
vised clustering algorithms. First, the consensus clustering 
with HCL analysis revealed 2 subgroups in S-EPNs, and 
the same groups were identified using the NMF method 
(Figure 1A and Supplementary Figure S1). Group 1 (n = 18) 
consisted of 11 WHO grade I, 6 WHO grade II, and 1 WHO 
grade III tumors whereas Group 2 consisted of both WHO 
grade II (n = 8) and III (n = 1) tumors. The Heidelberg brain 
tumor classifier on DNA methylation array data assigned 
all Group 1 tumors to “ependymoma, myxopapillary” and 
5 Group 2 tumors to “ependymoma, spinal” (Figure 1B). 
The other 3 tumors in Group  2 were classified as “CNS 
high-grade neuroepithelial tumor with MN1 alteration,” 
“Plexus tumor,” and “control tissue, inflammatory tumor 
microenvironment,” and one with no matching meth-
ylation class (referred to as “Other” in Figure 1B). Based 
on these results, we annotated Group  1 as SP-MPE and 
Group 2 as SP-EPN (Figure 1B). To corroborate the clinical 
relevance of these subgroups, we analyzed 21 patients 
with known clinical outcome. We found that the SP-EPN 
subgroup was associated with unfavorable overall survival 
  
Table 1. Patient Characteristic of Pediatric Spinal Ependymoma 
Cohort





 Male 17 (63)
 Female 10 (37)
Histologic diagnosis 
 Myxopapillary ependymoma 11 (41)
 Ependymoma 14 (52)
 Anaplastic ependymoma 2 (7)
WHO tumor grade
 I 11 (41)
 II 14 (52)
 III 2 (7)
Initial tumor resection
 Partial 8 (30)
 Complete 17 (63)
 Missing 2 (7)
Follow-up
 Median follow-up (years) 3.6
Status
 Alive 24 (89)
 Dead 2 (7)
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(OS) compared with SP-MPE although the difference in OS 
was not statistically significant (log-rank test, P value = .38; 
Supplementary Figure S2). The median OS for the SP-EPN 
subgroup was 5.33 years while the median for the favor-
able SP-MPE was not reached.
We further investigated WHO grade II and grade III 
S-EPNs of our cohort in more detail as these tumors 
were distributed to both molecular subgroups (Figure 1B 
and Supplementary Figure S3). One patient with WHO 
grade III in SP-EPN was a female (7.3  years old) who is 
free from relapse after the partial resection. In con-
trast, the WHO grade III female patient in SP-MPE was of 
11.42  years of age with recurrence (time to recurrence: 
2  years) after the complete resection surgery (Figure 
1B and Supplementary Table S1). A  comparison of clin-
ical features revealed that patients with WHO grade II 
ependymoma in SP-EPN (n  =  4) were younger than pa-
tients in SP-MPE (n = 6) subgroup (median 9.9 years vs 
13.5  years). None of the patients with WHO grade II 
ependymoma in the SP-EPN subgroup relapsed or died 
from their disease, but one patient in SP-MPE did (Figure 
1B) relapse and died. For the SP-MPE subgroup, 4 out of 
5 WHO grade II ependymoma patients had a complete re-
section and showed a trend for better OS than all WHO 
grade II ependymoma patients in the SP-EPN subgroup 

































NMF Grade Surgery Status Gender Classifier
5
Non-negative matrix factorization (NMF)
Group 2Group 2Group 1
Figure 1. Pediatric spinal ependymomas comprise 2 subgroups. (A) Unsupervised consensus clustering (CC) and non-negative matrix factoriza-
tion (NMF) heatmaps displaying the 2 robust subgroups defined by DNA methylation profiles from 27 pediatric pediatric spinal ependymomas using 
the top 5000 most variably methylated CpG probes across all tumors. Significance of clustering in CC was measured using SigClust. Sample overlap 
between 2 methods, CC and NMF, was measured using a Rand index. (B) DNA methylation-based subgroup assignment by 2 unsupervised methods 
(CC and NMF), clinical features, sample classification by the Heidelberg DNA methylation classifier (Heidelberg), and age at diagnosis (in years) are 
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Pediatric S-EPN Subgroup-Specific Chromosomal 
Aberrations
To identify genetic alterations that correlate with sub-
groups, we analyzed DNA copy number profiles using 
the combined intensity values of the methylated and 
unmethylated probes. Consistent with the previous ge-
nomic characterizations of ependymoma, all samples in 
SP-MPE and SP-EPN groups displayed aneuploidy (Figure 
2A). The SP-MPE subgroup was characterized by a gain of 
chr5 and loss of chr10 (Figure 2B). Interestingly, the loss of 
chr22 was found in all 5 cases (4 WHO grade II and 1 WHO 
grade III EPN) in SP-EPN that were predicted as SP-EPN 
by the Heidelberg classifier but found in only one WHO 
grade II ependymoma (1 of 6 WHO grade II and 1 WHO 


















































































Figure 2. Copy number variations across 2 molecular subgroups of pediatric spinal ependymal tumors. (A) Genome-wide view of copy number 
alterations in 27 pediatric spinal ependymomas estimated from DNA methylation arrays subdivided by 2 subgroups: SP-MPE and SP-EPN. The 
heatmap displays gains (red) and losses (blue) of each chromosome (column) across each sample (row) subdivided by SP-MPE and SP-EPN. (B) 
Summary of chromosomal imbalances showing distinct alterations within 2 molecular subgroups of ependymal tumors. Copy number plots were 
generated based on DNA methylation, color code for losses (blue) and gains (red) of chromosomal profiles. Results were plotted as frequencies at 
which these aberrations occurred within each molecular subgroup; significance is illustrated by P values, which indicate distinct distributions of 
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pediatric spinal subgroups, we performed copy number 
analysis using GISTIC 2.0 that revealed a much lower 
number of focal copy number alterations. The only focal 
and recurrent amplification was observed in SP-MPE 
(4/18; 22%) encompassing HOXB cluster genes (17q21.32) 
that include 9 consecutive HOXB genes (HOXB1-B9) and 
2 micro-RNAs (miR-10a and miR-196a-1; Supplementary 
Table S2). Less frequent recurrent deletions in and around 
ALG10 (12q12; 3/18), TP73 (1p36.32; 2/18) and significant 
non-recurrent deletions in and around miR-202 (10q26.3), 
POTEA (8p11.1), IDI1 (10p15.3), and miR-483 (11p15.5) 
were found in SP-MPE (Supplementary Table S3). In con-
trast, the SP-EPN subgroup had no significant recurrent 
copy number alterations except the non-recurrent deletion 
around ALG10 (12q12; 1/9). SP-EPN with MYCN amplifica-
tion has been recently proposed as a new ependymoma 
subgroup. We observed MYCN amplification in one 
tumor, which was predicted to be a “Plexus Tumor” by the 
Heidelberg brain tumor classifier (Supplementary Table 
S1). Interestingly, this tumor sample was also classified as 
MGMT methylated.
Pediatric SP-MPE Tumors Exhibit Increased 
Expression of Mitochondrial Metabolism 
Pathways
To delineate characteristic biological processes and 
signaling pathways for each of these pediatric SP-EPN sub-
groups, we performed GSEA with the ranked gene list. We 
found that pathways involved in mitochondrial function 
(cellular respiration, oxidative phosphorylation, aerobic 
respiration, and mitochondrial translation) and structure 
(mitochondrial respiratory chain complex assembly, and 
electron transport chain), and cellular energy metabolism 
(cellular aldehyde metabolic process, nucleoside triphos-
phate metabolic process, and fatty acid beta-oxidation) 
defined SP-MPE (Figure 3A and Supplementary Table S4). 
There was no significant gene set enriched in SP-EPN at 
FDR less than 0.05; however, potassium ion transport 
was detected as the top gene set with FDR less than 0.17 
(Supplementary Table S5). The majority of oxidative phos-
phorylation (OXPHOS) metabolic pathway genes across 
5 complexes showed high expression in SP-MPE when 
compared to SP-EPN (Figure 3B). To validate the OXPHOS 
signature observed at the transcriptional level in SP-MPE, 
we performed Western blot analysis of OXPHOS com-
plexes. We examined 5 OXPHOS proteins: NADH: ubiqui-
none oxidoreductase subunit B8 (NDUFB8); succinate 
dehydrogenase complex iron-sulfur subunit B (SDHB); 
ubiquinol-cytochrome c reductase core protein II (UQCR2); 
mitochondrially encoded cytochrome c oxidase II (COXII); 
ATP synthase, H+ transporting, mitochondrial F1 com-
plex, alpha subunit (ATP5A) in pediatric S-EPN samples. 
We found that the total protein levels of 5 OXPHOS com-
plexes were high in SP-MPE (8.6  ± 3.3) compared with 
SP-EPN (3.9 ± 1.2) and contributed by complexes II, III, and 
IV. Interestingly, the levels of complex V were reduced in 
SP-MPE and there were no differences in complex I across 
2 subgroups (Figure 3C).
We next aimed at evaluating the previously identi-
fied subgroup-specific transcriptional signatures4 in our 
pediatric cohort of 27 SP-EPN patients. We observed 
consistent expression patterns of SP-MPE and SP-EPN 
subgroup-specific signature genes in pediatric SP-EPN 
(Supplementary Figure S4). More than half of the SP-EPN 
signature genes identified in our dataset, including 
HOXA13, NEFL, HNF1B, KMO, and HOXB13, showed in-
creased expression in SP-MPE (FDR < 0.05, Wilcoxon’s 
rank-sum test), whereas 3 genes, RAB3C, VEPH1, and 
WT1, among the 18 SP-EPN signature genes showed high 
expression levels in the SP-EPN subgroup. While we ob-
served gene signatures reflecting the underlying transcrip-
tional profiles of pediatric SP-EPN subgroups, the power of 
this analysis was limited due to the small sample size.
DNA Methylation Alterations Are Enriched 
for Probes at Enhancers and Developmental 
Transcription Factors Binding Sites
To characterize candidate biological processes altered by 
differential methylation between the subgroups, we iden-
tified differentially methylated regions (DMRs) and per-
formed the genomic regions enrichment analysis. DMRs 
with high methylation levels in SP-MPE (57% of 247 DMRs 
at FDR < 0.05) showed an unexpected enrichment for genes 
encoding immune-related proteins, including MHC protein 
complex (FDR = 2.5 × 10−03, Binomial test; HLA-DMB, HLA-
DOA, and HLA-G) and TAP complex (FDR  =  2.14  × 10−03; 
TAP2 and TAPBP; Supplementary Table S6). We also ob-
served a significant enrichment of genes involved in pro-
tein tyrosine kinase collagen receptor activity (FDR = 4.21 × 
10−03) and HMG box domain binding (FDR  =  9.69  × 
10−03). In contrast, DMRs with low methylation levels in 
SP-MPE were enriched for several developmental pro-
cesses, including anterior/posterior pattern specification 
(FDR = 3.95 × 10–15), trophoblast giant cell differentiation 
(FDR = 2.23 × 10−03), and cell fate specification (FDR = 2.01 × 
10−02; Supplementary Table S7). We also observed a signif-
icant enrichment of HOX genes (HOXA9, 11, 13; HOXB2, 4, 
5, 6, 9, 13; HOXC9, 10, 11; HOXD3 and HOXD4) associated 
with low methylated DMRs in SP-MPE (Figure 4A). Of note, 
HOX gene overexpression is associated with SP-EPN, thus 
validating our approach.
The significant DMRs consisted of on average 10 CpG 
probes that spanned over 5  kb from the TSS, indicating 
DNA methylation changes preferentially occurring in distal 
regions (Figure 4B), suggesting enhancers were affected 
by changes in methylation. We, therefore, sought to iden-
tify subgroup-specific DNA methylation changes in distal 
enhancer regions. To this end, we selected CpG probes that 
are greater than ±2 kb from a known TSS, resulting in a set 
of 147 195 distal probes. The majority of distal probes had 
low methylation (91% of 1536 probes) versus high meth-
ylation levels for SP-MPE compared to SP-EPN (|∆β| > 0.2 
and FDR < 0.05; Supplementary Figure S5). To identify 
target genes regulated by the distal regulatory elements, 
we analyzed expression data for 10 genes upstream and 
10 genes downstream from each significant distal probe. 
We identified a total of 247 distal probe–gene pairs with 
low methylation and increased expression levels and only 
4 distal probe–gene pairs with high methylation and de-
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Figure 3. Mitochondrial metabolism pathways define the SP-MPE subgroup. (A) Gene set enrichment analysis plot for the top 3 significantly 
enriched signaling pathways: cellular respiration, OXPHOS pathway, and mitochondrial respiratory chain complex assembly identified on com-
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S6). Notably, oncogenes exemplified by CDK6, HOXD11, 
IDH2, and JAK2, and genes involved in oxidative phos-
phorylation (COX4I1, DLAT, NDUFA5, and NDUFA6), were 
overexpressed in SP-MPE and demonstrated low methyla-
tion (Supplementary Table S8). In contrast, long intergenic 
non-protein-coding RNAs (LINC01102 and LINC01114) 
and the gene encoding POU-domain containing proteins 
(POU3F3 and PANTR1) which have decreased expres-
sion in SP-MPE demonstrated high methylation levels 
(Supplementary Table S9). We next sought to determine 
which upstream transcription factors (TFs) control the ac-
tivity of these regulatory elements. The integrative anal-
ysis with ELMER identified 38 significantly enriched TF 
binding motifs within candidate regulatory regions asso-
ciated with 247 SP-MPE’s distal probes (Supplementary 
Table S10). The most highly enriched motifs corresponded 
to several homeobox (HOX) family members, including 
HOXB13, HOXD12, HOXD9, HOXA13, and HOXC13 (Figure 
4C). Considerable evidence demonstrates that when a 
group of enhancers is co-ordinately altered in a specific 
sample subset, which is often the result of an altered up-
stream master regulator TF in the gene regulatory network. 
Taking into account these known biological phenomena, 
we performed an integrative analysis, thereby identifying 
a small set of potential candidate master TFs, including 
homeodomain-containing TFs (BARX2 and HNF1B) and 
zinc finger TFs (ZIC3 and ZNF423; Supplementary Table 
S10).
Discussion
During the past decade, advancing technologies have pro-
vided an unprecedented view of the genomic landscape of 
CNS tumor types, including ependymoma. These studies 
showed that ependymoma is a molecularly heterogeneous 
group of tumors, which can be classified into 9 different 
subgroups based on major CNS compartments. One lim-
itation of these studies, however, is that the cohorts were 
comprised predominantly of young adult or adult patients. 
Importantly, ependymoma occurs in both pediatric and 
adult patients, and the location and behavior of the tumors 
vary in an age-dependent fashion. To elucidate genomic 
features specific to pediatric SP-EPN, we selected a co-
hort of 27 pediatric patients and performed an integrative 
DNA methylation and transcriptomics study. We discov-
ered that SP-EPN in children is stratified into 2 subgroups 
with distinct genomic and transcriptomic features. To our 
knowledge, the discovery of 2 molecular subgroups in this 
study represents the first effort to characterize SP-EPN in 
children. Notably, these primary subgroups emerge from 
unsupervised analysis and are well-supported by a re-
cently proposed DNA methylation-based classifier for 
CNS tumors.
The majority of pediatric SP-EPNs in our cohort could 
be assigned to 1 of 2 recently defined DNA methylation-
based ependymoma subgroups: SP-MPE or SP-EPN.4 All 
pediatric patients with histologically defined WHO grade 
I  showed a perfect match with SP-MPE, whereas WHO 
grade II and grade III tumors were heterogeneous by 
DNA methylation profiling and distributed to both sub-
groups. The importance of this change in-group alloca-
tion from histology to the molecular group for a subset 
of pediatric tumors is unclear. In fact, the Consortium to 
Inform Molecular and Practical Approaches to CNS Tumor 
Taxonomy (cIMPACT-NOW) working group recommended 
designating myxopapillary ependymoma as WHO grade 
II in their most recent update 7.20 Nevertheless, pediatric 
patients with WHO grade II or aggressive WHO grade III 
tumors in the SP-MPE subgroup are slightly older and 
with longer survival compared to tumors of the same 
grades in SP-EPN. Interestingly, DNA methylation pro-
filing of adult ependymomas had previously shown that a 
subset of spinal WHO grade II tumors could be classified 
as SP-MPE.21 Furthermore, a study with gene expression 
profiling of 35 SP-EPNs (~80% from adult patients) demon-
strated that myxopapillary and WHO grade II SP-EPN are 
molecularly distinct entities and a subset of grade II tumors 
could either be clustered with the myxopapillary group or 
not be firmly assigned to any subgroup.22 Together, these 
findings indicate that WHO grade II SP-EPNs are heteroge-
neous and histopathological evaluation alone is not suffi-
cient. Thus, DNA methylation profiling may help refine the 
classification of these tumors.
In our study, the complete or partial gain of chromosome 
5 and loss of chromosome 10 were the most significant ge-
nomic alterations, occurring commonly in SP-MPE tumors, 
but not in SP-EPN. Also, a relatively low number of focal and 
recurrent alterations was detected in our cohort, which is 
consistent with previous genomic studies of ependymoma. 
Strikingly, the only recurrent, focal amplification on the 
chromosomal arm 17q involving HOXB cluster genes at 
17q21 was found in SP-MPE tumors. Interestingly, MYCN 
amplification was detected in one grade II spinal tumor 
that was classified as a “Plexus tumor” by the Heidelberg 
brain tumor classifier. All other grade II/III spinal tumors in 
our cohort did not harbor MYCN amplification, the finding 
contrasts with recent studies,6 where an aggressive sub-
group of SP-EPN characterized by MYCN amplification 
(SP-EPN-MYCN) was identified. The 3 SP-EPN-MYCN co-
hort from previously published studies consisted of a total 
of 25 patients with a median age of 32 years, suggesting 
that the extremely rare MYCN amplification is likely to be 
associated with 5 different oxidative phosphorylation complexes. A row represents a gene and the column indicates the sample. The normalized 
expression value of each gene is indicated by color intensity, with red/blue representing high/low expression. (C) Western blot showing 5 OXPHOS 
proteins (ATP5A, COXII, NDUFB8, SDHB, and UQCRC2) in SP-MPE (n = 5) and SP-EPN (n = 5). I, II, III, IV, and V indicate OXPHOS complexes. 
GAPDH is internal control. Mean of 5 OXPHOS protein levels quantified from WB and normalized to GAPDH are shown as well as for each com-
plex separately. P value from Mann–Whitney test. ATP5A, ATP synthase subunit alpha 5; COXII, cytochrome oxidase subunit II; NDUFB8, NADH: 
ubiquinone oxidoreductase subunit B8; SDHB, succinate dehydrogenase [ubiquinone] iron-sulfur subunit B; UQCRC2, ubiquinol-cytochrome C 
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a specific characteristic of SP-EPN from adult patients with 
highly aggressive disease.6 Less frequent or non-recurrent 
focal and statistically significant deletions found in SP-MPE 
included genes involved in the p53 pathway (CD81, HRAS, 
CTSD, WRAP73, and PIDD1). Although the loss of chromo-
some 22 was noted in all grade II tumors of SP-EPN, it was 
not frequently found in our grade II tumors assigned to the 
SP-MPE group. It remains to be seen whether the loss of 
chromosome 22 plays a role in grade II SP-EPNs in children.
In addition to genomic differences, pediatric spinal ep-
endymal tumors showed subgroup-specific transcrip-
tional differences. For instance, cellular and mitochondrial 
energy metabolism genes were most active in SP-MPE 
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Figure 4. SP-MPE exhibits DNA methylation profiles distinct from SP-EPN. (A) Representative plot of the differentially methylated region (DMR) in 
SP-MPE compared to SP-EPN tumors for HOX genes (HOXB6 and HOXA10). The points represent DNA methylation levels (β value) for each tumor 
sample and smoothed lines indicate the mean β values at the CpG probe for SP-MPE and SP-EPN. (B) Bar graphs displaying association of genomic 
regions to the transcription start site (TSS) of all DMRs with low (left) and high (right) methylation levels in SP-MPE when compared with SP-EPN 
tumors. The distance between CpG probe location and their putatively regulated genes is divided into 4 separate bins (x-axis) and the percentage 
of genes in each genomic region (y-axis) is shown. The absolute number is also listed on the top of each bar graph. (C) Motif enrichment plot shows 
the enrichment levels (odds ratio >2.5) for the most significant motifs based on ELMER supervised analysis. A complete list of significant motifs 
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Notably, a number of genes related to the OXPHOS 
pathway were overexpressed in the SP-MPE subgroup 
compared to the SP-EPN subgroup. Our integrative anal-
ysis of DNA methylation and gene expression at enhancer 
regions also suggested the involvement of OXPHOS 
genes in SP-MPE tumors, providing evidence of the un-
derlying biology and pathway activation in the SP-MPE 
subgroup. Previous pathological studies showed that 
myxopapillary ependymomas were frequently positive 
for COX2,24,25 a complex IV subunit of the mitochondrial 
respiratory chain, OXPHOS, which fits with our present 
results. A  large body of evidence suggests that COX2 is 
upregulated in various cancers and plays roles in pro-
moting cell proliferation, neovascularization, growth, 
and metastasis of tumor cells.26–28 While this observation 
is interesting, definite conclusions regarding COX2 de-
tection and its role in pediatric SP-MPE tumors will have 
to await validation in larger patient cohorts. Besides 
OXPHOS pathway activation, our gene expression ana-
lyses furthermore showed high expression of previously 
identified SP-MPE subgroup-specific signature genes, in-
cluding HNF1B and HOXB13 that belong to the homeobox 
gene family. Several previous studies revealed that ho-
meobox genes, especially HOXB13, were exclusively ex-
pressed in spinal myxopapillary,29,30 indicating HOXB13 
as a diagnostic marker to distinguish SP-MPE subgroup 
from other spinal subgroups. It is also worth noting that 
the homeobox family of genes play important roles in 
stem cell renewal, cell fate determination, and specify the 
patterning of body segments along the anterior–posterior 
axis, where HOXB13 expression is limited to the lumbar/
sacral regions of the spinal cord, the prominent locations 
for myxopapillary ependymomas.23,29,31 Furthermore, our 
study revealed enrichment for homeobox TF binding mo-
tifs in SP-MPE tumors with methylated DMR patterns at 
enhancer regions. These master regulatory TFs include 
HNF1B, a member of the hepatocyte nuclear factor family, 
which regulates the complex gene networks involved in 
lipid, carbohydrate, and protein metabolism and plays an 
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studies to validate these findings and provision of greater 
details in the various manifestations of associated pro-
cesses may reveal new opportunities for targeted ther-
apies for these rare SP-MPE tumors in children.
A major limitation of studying a rare cancer such as pedi-
atric SP-EPN is the relatively low number of tumor samples 
with available tissue for a more comprehensive molecular 
profiling. Multivariable analysis with regard to survival and 
prognostic factors was not feasible due to small patient num-
bers. The validation in a larger and independent pediatric 
SP-EPN cohort is needed to further establish the difference 
between SP-MPE and SP-EPN including clinical prognosis.
In summary, we uncovered 2 molecular subgroups of 
pediatric SP-EPN that differ in their genomic and tran-
scriptional characteristics. Specifically, we discovered that 
transcriptional networks associated with oxidative phos-
phorylation were enriched in SP-MPE. Furthermore, our 
results suggest that alterations in methylation patterns at 
key enhancers contribute to alterations in gene expres-
sion. Finally, we identified putative master regulatory 
TFs that may govern these changes in gene expression. 
This multifaceted analysis provides a valuable resource 
for assessing genomic alterations across the spectrum of 
pediatric spinal tumors. While further studies with whole-
genome and transcriptome analysis in expanded cohorts 
are warranted, this study provides a strong basis for func-
tional follow-up and investigation of potential therapeutic 
targets in young patients with SP-EPN.
Supplementary Material
Supplementary material is available at Neuro-Oncology 
Advances online.
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